Protocol Ledger

Academic / Cooperative Group · Consolidated Sponsor Hub

UC Davis: Clinical Trials & FDA Approval Profile

UC Davis (Sacramento, CA) sponsors 38 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 23 active protocols (15 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)26.3%
Median Closed Enrollment vs National (145 pts)16 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for UC Davis
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)38
Active Pipeline (Recruiting Now)23 (15)
Completed vs Stopped Early5 / 10 (26.3%)
Median Closed Actual Enrollment16 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With UC Davis
Hospital Research SiteLocationShared Protocols
UC Davis Comprehensive Cancer CenterSacramento, CA34
UC San Diego Health and Moores Cancer CenterSan Diego, CA2

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for UC Davis Health across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the UC Davis Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI